279 related articles for article (PubMed ID: 15693134)
21. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines.
Murata M; Nabeshima S; Kikuchi K; Yamaji K; Furusyo N; Hayashi J
Cytokine; 2006 Feb; 33(3):121-8. PubMed ID: 16522372
[TBL] [Abstract][Full Text] [Related]
22. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
Avnet S; Cenni E; Perut F; Granchi D; Brandi ML; Giunti A; Baldini N
Int J Oncol; 2007 Feb; 30(2):469-76. PubMed ID: 17203230
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
24. Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells.
Gómez-Benito M; Balsas P; Bosque A; Anel A; Marzo I; Naval J
FEBS Lett; 2005 Nov; 579(27):6217-22. PubMed ID: 16246331
[TBL] [Abstract][Full Text] [Related]
25. Interferon-alpha-induced apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent and -independent manner.
Yanase N; Kanetaka Y; Mizuguchi J
Oncol Rep; 2007 Oct; 18(4):1031-8. PubMed ID: 17786370
[TBL] [Abstract][Full Text] [Related]
26. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
27. Alpha-interferon and its effects on signalling pathways within cells.
Caraglia M; Vitale G; Marra M; Budillon A; Tagliaferri P; Abbruzzese A
Curr Protein Pept Sci; 2004 Dec; 5(6):475-85. PubMed ID: 15581417
[TBL] [Abstract][Full Text] [Related]
28. New developments in interferon therapy.
Tossing G
Eur J Med Res; 2001 Feb; 6(2):47-65. PubMed ID: 11313191
[TBL] [Abstract][Full Text] [Related]
29. [Interferon--a new therapeutic principle].
Micksche M
Wien Med Wochenschr; 1993; 143(16-17):408-12. PubMed ID: 8273362
[TBL] [Abstract][Full Text] [Related]
30. The dilemma of the strive for apoptosis in oncology: mind the heart.
Perik PJ; de Vries EG; Gietema JA; van der Graaf WT; Sleijfer DT; Suurmeijer AJ; van Veldhuisen DJ
Crit Rev Oncol Hematol; 2005 Feb; 53(2):101-13. PubMed ID: 15661561
[TBL] [Abstract][Full Text] [Related]
31. In vitro modelling of human tumour behaviour in drug discovery programmes.
Baguley BC; Marshall ES
Eur J Cancer; 2004 Apr; 40(6):794-801. PubMed ID: 15120035
[TBL] [Abstract][Full Text] [Related]
32. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.
Caraglia M; Marra M; Tagliaferri P; Lamberts SW; Zappavigna S; Misso G; Cavagnini F; Facchini G; Abbruzzese A; Hofland LJ; Vitale G
Curr Cancer Drug Targets; 2009 Aug; 9(5):690-704. PubMed ID: 19508175
[TBL] [Abstract][Full Text] [Related]
33. [Perspectives of medical therapy of solid tumours].
Koza I
Vnitr Lek; 2001 Aug; 47(8):510-5. PubMed ID: 15633386
[TBL] [Abstract][Full Text] [Related]
34. [Principles of drug therapy of malignant tumors: determinants of the efficacy of cytostatic agents].
Jeney A; Kralovánszky J
Orv Hetil; 1999 Jun; 140(24):1339-45. PubMed ID: 10439634
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic determinants of the activity and toxicity of antitumour agents.
Newell DR
Cancer Surv; 1989; 8(3):557-603. PubMed ID: 2701085
[TBL] [Abstract][Full Text] [Related]
36. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.
Murphy D; Detjen KM; Welzel M; Wiedenmann B; Rosewicz S
Hepatology; 2001 Feb; 33(2):346-56. PubMed ID: 11172336
[TBL] [Abstract][Full Text] [Related]
37. Antiapoptotic effect of interferon-alpha on hepatic stellate cells (HSC): a novel pathway of IFN-alpha signal transduction via Janus kinase 2 (JAK2) and caspase-8.
Saile B; Eisenbach C; El-Armouche H; Neubauer K; Ramadori G
Eur J Cell Biol; 2003 Jan; 82(1):31-41. PubMed ID: 12602946
[TBL] [Abstract][Full Text] [Related]
38. Alpha-interferon and its effects on signal transduction pathways.
Caraglia M; Marra M; Pelaia G; Maselli R; Caputi M; Marsico SA; Abbruzzese A
J Cell Physiol; 2005 Feb; 202(2):323-35. PubMed ID: 15389589
[TBL] [Abstract][Full Text] [Related]
39. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression.
Arora T; Jelinek DF
J Biol Chem; 1998 May; 273(19):11799-805. PubMed ID: 9565604
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
